Date: 2016-06-15
Type of information: Series B financing round
Company: Allecra Therapeutics (Germany - France)
Investors: Delos Capital (USA - NY) Forbion Capital Partners (The Netherlands) Edmond de Rothschild Investment Partners (France) EMBL Ventures (Germany) Nicholas Benedict
Amount: €22 million
Funding type: series B financing round
Planned used: The proceeds will fund Phase 2 development of AAI202, Allecra’s proprietary, novel antibiotic combination designed to treat drug-resistant Gram-negative bacterial infections. AAI202 is a combination of a powerful ?-lactam antibiotic together with a proprietary, novel extended spectrum ?-lactamase inhibitor. The combination is designed for use as broad-spectrum antibacterial therapy to treat hospitalized patients who contract infections caused by Gram-negative bacteria proven or suspected to express certain resistance mechanisms, particularly extended-spectrum ?-lactamases (ESBLs).
FDA has granted QIDP status [Qualified Infectious Disease Product] for AAI202, including eligibility for Fast-Track designation in the USA.
Others: * On June 15, 2016, Allecra Therapeutics announced the closing of a €22 Million Series B investment round. The round was led by new investor, Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra’s co-Founder Nicholas Benedict also participated.
Therapeutic area: Infectious diseases
